Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2/PHASE3

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-16

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase II/III seamless design, randomized, double-blind, paralleled-group, placebo-controlled study to evaluate the efficacy and safety of Xianglei Tangzu Gao for the treatment of Wagner grade II diabetic foot ulcers. The primary endpoint is the proportion of subjects with complete closure of target ulcer during the 16-week treatment phase.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer

NCT05930210

Diabetic Foot Ulcer Foot Ulcer Diabetes Mellitus +1 more

RECRUITING PHASE3

Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers

NCT00709514

Chronic Diabetic Foot Ulcer

COMPLETED PHASE2

A Study of GM-XANTHO in Pressure Ulcer Patients

NCT05199077

Pressure Ulcer Diabetes Mellitus

NOT_YET_RECRUITING PHASE2

Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer.

NCT02554851

Foot Ulcer, Diabetic Epidermal Growth Factor

UNKNOWN PHASE3

TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers

NCT00389636

Diabetic Foot Ulcer

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Foot Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Xianglei Tangzu Gao plus Standard of Care

Xianglei Tangzu Gao will be applied twice daily for up to 16 weeks to the Target Ulcer.

Group Type EXPERIMENTAL

Xianglei Tangzu Gao

Intervention Type DRUG

Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica

Vehicle Cream plus Standard of Care

Vehicle cream will be applied twice daily for up to 16 weeks to the Target Ulcer

Group Type PLACEBO_COMPARATOR

Vehicle Cream

Intervention Type OTHER

Cream base of Xianglei Tangzu Gao

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Xianglei Tangzu Gao

Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica

Intervention Type DRUG

Vehicle Cream

Cream base of Xianglei Tangzu Gao

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects, male or female, aged 18 to 80 years (inclusive) with Type 1 or Type 2 diabetes undergoing therapy for glycemic control using available diabetes drugs including insulin.
2. Subject has a glycosylated hemoglobin, HbA1c ≤ 12%.
3. Diagnosis with Diabetic Peripheral Neuropathy (DPN) or vascular disease defined by Chinese guidelines for diagnosis and treatment of diabetic foot (2020 version). Subject has adequate vascular perfusion of the affected limb, no obvious clinical manifestations of lower limb ischemia, confirmed by Ankle-Brachial Index (ABI) ≥ 0.8 and ≤ 1.3, or transcutaneous pressure of oxygen (TcPO2) \> 30 mmHg on at least one lead.
4. An ulcer of Wagner Grade II.
5. Presence of at least one diabetic foot ulcer that meets all of the following criteria:

1. Ulcer size (area) is \> 1 cm2 and ≤ 25 cm2 (post-debridement at time of screening and randomization)
2. Ulcer is located on or below the malleoli and presents duration of between 4 weeks and 12 months (at time of screening).
3. If there are more than two ulcers, there should be a minimum 3 cm margin between the qualifying Target Ulcer and any other ulcers on the specified foot (post- debridement).
4. No active infection by clinical inspection as defined by IDSA/IWGDF criteria. Note: If the subject has more than one qualifying diabetic foot ulcer, the most severe ulcer will be designated as the target ulcer. Severity will be determined by the investigator's assessment.
6. Subject, if a female of child-bearing potential, has a negative serum pregnancy test at screening, and willing to use 2 medically accepted methods of contraception (e.g., barrier contraceptives \[female condom, or diaphragm with a spermicidal gel\], hormonal contraceptives \[implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings\], and intrauterine devices) during the study (excluding women who are not of childbearing potential and/or who have been sterilized).
7. Subject should be able to walk and stand on the non-target ulcer limb.
8. Subject is willing to use an off-loading device for the target ulcer on the plantar while ambulation for the duration of the study
9. Subject and/or trained identified caregiver is able and willing to comply with study procedures and appropriate dressing changes.
10. A signed and dated informed consent form has been obtained from the subject prior to any study-related procedures being performed.

Exclusion Criteria

1. In response to the standard of care, ulcer size reduction is \> 30% during the two-week run-in Screening Period (between the first Screening Visit/V0 and Baseline/V2 randomization).
2. Ulcers with exposed bone or associated with osteomyelitis. Note: The osteomyelitis should be ruled out by clinical examination (probing of the wound) and X-ray findings.
3. Presence of necrosis, purulence, or sinus tracts that cannot be removed by debridement.
4. Laboratory values at Screening of:

1. White Blood Cells (WBC) \< 3.0 X 109 cells/L, \> 12.0 X 109 cells/L
2. C-Reactive Protein (CRP) \>100 mg/L
3. Liver function studies \[Total bilirubin, aspartate aminotransferase (AST) and alanine transaminase (ALT)\] \> 3x the upper limit of normal
4. Albumin \< 25 g/L
5. Renal function studies \[Serum Creatinine\] \> 3x the upper limit of normal
6. Hemoglobin\< 100 g/L
5. Presence of any clinically significant medical condition(s) in medical history during screening period that, in the opinion of the investigator, could interfere with wound healing, including but not limited to the following:

1. Acute or unstable Charcot foot
2. Current sepsis
3. Active malignant disease. A subject, who has had a malignant disease in the past, was treated, and is currently disease-free, may be considered for study entry.
4. Acquired immune deficiency syndrome (AIDS) or HIV positive.
5. Severe cerebrovascular lesion (acute or significant clinical manifestation) and severe cardiac dysfunction (NYHA class III or IV) such as congestive heart failure, myocardial infarction, or coronary artery bypass grafting, or percutaneous transluminal coronary angioplasty was performed within the last 6 months.
6. Subject is currently receiving (i.e., within 30 days of randomization visit) or scheduled to receive any of following medication or therapies, could interfere with wound healing during the study.

1. immunosuppressants (including chronic systemic and topical steroids)
2. cytotoxic chemotherapy
3. cytostatic therapy
4. negative pressure wound therapy
5. autoimmune disease therapy
6. dialysis
7. lower limb revascularization surgery
8. intravenous infusion of growth factors
9. use of any investigational drug(s)
7. Previous use of bioengineered tissue or skin substitutes on potential target ulcers.
8. Subjects who need to stand continuously for more than 4 hours / day and have difficulty complying with off-loading instructions.
9. A psychiatric condition (e.g., suicidal ideation), current or chronic alcohol or drug abuse, determined from the subject's medical history, which, in the opinion of the investigator, may pose a threat to subject compliance.
10. Has any other factor which may, in the opinion of the investigator, compromise participation and/or follow-up in the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No